Basic Information
| LncRNA/CircRNA Name | LINC00152 |
| Synonyms | CYTOR, C2orf59, LINC00152, NCRNA00152 |
| Region | GRCh38_2:87454781-87636740 |
| Ensemble | ENSG00000222041 |
| Refseq | NR_024204 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot |
| Sample | lung cancer tissues, cell lines (MDA-MB-231, MDA-MB-469, MDAMB-361, MCF-7, T47D, MDA-MB-435, BT474, BT20, and BT483,184A1 and MCF-10A) |
| Expression Pattern | up-regulated |
| Function Description | linc00152 was highly expressed in all basal-like cell lines and in the majority of TNBC tissues. Linc00152 suppression by shRNA significantly inhibited invasion and colony growth. Such suppression also triggered apoptosis in vitro and inhibited tumor growth in vivo.linc00152 partially enhanced breast cancer tumorigenesis by inactivation of the BRCA1/PTEN through DNA methyltransferases.linc00152 as a promising biomarker and therapeutic target for human TNBC treatment. |
| Pubmed ID | 29156515 |
| Year | 2017 |
| Title | Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer. |
External Links
| Links for LINC00152 | GenBank HGNC NONCODE |
| Links for triple negative breast cancer | OMIM COSMIC |